WCD 2023: Advancing Patient-specific Safety for Cancer Care Worldwide
- February 4, 2023
On 4 February, 2023, DOSIsoft supports the World Cancer Day (WCD)
DOSIsoft extends its condolences to Prof. François Eschwege
- January 11, 2023
Happy New Year from DOSIteam
- January 5, 2023
Enjoy successful dosimetry projects in Radiotherapy & Nuclear Medicine during 2023!
ICARE: winning solution for the MICCAI 2022 challenge: HEad and neCK TumOR (HECKTOR) for the outcome prediction task from PET/CT.
- September 30, 2022
The Individual Coefficient Approximation for Risk Estimation (ICARE) Model was ranked as the winning solution and presented by Louis Rebaud and Thibault Escobar at the 25th international conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI) congress in Singapore.
Thibault Escobar: First Place Winner of the PIDSC Young Investigator Award 2022
- September 27, 2022
Thibault Escobar was the first place winner with the scientific work on “Radiomic decision maps reveal patterns discriminating between glioma progression and radiation-induced necrosis in static and dual time [18F]-FDOPA PET”.
Brazilian hospital streamlines pre-radiotherapy workflow with phantom-less QA solution
- July 20, 2022
Hospital Unimed Bauru clinicians use Elekta’s novel EPID-based patient QA software to easily check RT beams before treatment. This phantom-less pretreatment QA solution has proven easy to use, saves time & gives staff confidence.
Patient QA Product Show at AAPM 2022
- June 23, 2022
The American Association of Physicists in Medicine (AAPM) Annual Meeting
July 10-14, 2022
Washington, DC, US
Patient QA demonstration at IUPESM WC2022
- June 13, 2022
World Congress on Medical Physics and Biomedical Engineering (IUPESM WC2022)
June 12 – 17, 2022
ABFM | CBFM 2022
- June 13, 2022
Congresso Brasileiro de Física Médica
June 8-11, 2022
[HCB News] Faster, better, safer: The latest in PET and SPECT
- June 3, 2022
Manufacturers in the PET and SPECT space are focusing on decreasing scan times, improving image quality to see smaller irregularities and lowering ra-diation dose. In nuclear medicine, product develop-ment has also focused on researching new radiotracers. There are also several preclinical devices in the research stages. Here’s a look at what’s new and what’s to come in the future.